Truist analyst Les Sulewski lowered the firm’s price target on Biote (BTMD) to $4 from $5 and keeps a Buy rating on the shares as part of a broader research note on biopharma previewing Q1 results. Outperformance across the firm’s Spec Pharma universe will be tapered this time around as abnormal winter conditions, increased prior authorization friction, and benefit resets weigh on earnings, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTMD:
- Biote Updates April 2026 Investor Presentation on Growth
- Inventory Forecasting Woes: Biote Corp. Faces Material Risk From Demand Volatility and Stock Management Challenges
- Biote Corp. Earnings Call Maps Pain Now, Promise Later
- Biote price target lowered to $2 from $3 at B. Riley
- Biote price target lowered to $3 from $4.50 at Roth Capital